Making a Difference with Early Identification and Treatment of Patients with NTRK Gene FusionsVideo Categories: NTRK Gene Fusions
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for TRK fusion–positive tumors early for improved clinical outcomes.
Ken Schaecher, MD, presents his own personal opinion on the challenges of concerns related to costs of treatment by oncologists and why they should not ignore them. Supported through funding from Incyte
Alexander Bastian says the most important thing to come out of ASH that will improve standard of care is the variety of treatments coming available, including a new drug from Amgen for treating ALL.